High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-κB ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis

Clinical Biochemistry

Volumn 41, Issue 9, 2008, Pages 746-749

  Pilichou, Anastasia ^a   Papassotiriou, Ioannis ^b   Michalakakou, Kelly ^b   Fessatou, Smaragdi ^a   Fandridis, Emmanuel ^a   Papachristou, George ^a   Terpos, Evangelos ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^c 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

Knee osteoarthritis; Osteoprotegerin (OPG); Receptor activator of nuclear factor B ligand (RANKL); Serum; Synovial fluid

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SYNOVIAL FLUID LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID;

EID: 43449128066     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.02.011     Document Type: Article

References (10)

1. Terpos E., Szydlo R., Apperley J.F., et al. Soluble receptor activator of nuclear factor kappa-B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102 (2003) 1064-1069
2. Kim K.W., Cho M.L., Lee S.H., et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunol Lett 110 (2007) 54-64
3. Fonseca J.E., Cortez-Dias N., Francisco A., et al. Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. Clin Exp Rheumatol 23 (2005) 185-192
4. Logar D.B., Komadina R., Prezelj J., Ostanek B., Trost Z., and Marc J. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab 25 (2007) 219-225
5. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96 (1999) 3540-3545
6. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
7. Mountzios G., Dimopoulos M.A., Bamias A., et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 46 (2007) 221-229
8. Skoumal M., Kolarz G., Haberhauer G., Woloszczuk W., Hawa G., and Klingler A. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 26 (2005) 63-69
9. Haynes D.R., Barg E., Crotti T.N., et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 42 (2003) 123-134
10. Andersson M.K., Lundberg P., Ohlin A., et al. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients. Arthritis Res Ther 9 (2007) R18